Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 Michigan Avenue Northwest
Washington, DC 20010Phone+1 202-476-2800Fax+1 202-476-5685
Education & Training
- Johns Hopkins Bloomberg School of Public HealthPhD, 2005 - 2009
- Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2004 - 2008
- NYU Grossman School of MedicineResidency, Pediatrics, 2001 - 2004
- University of Illinois College of MedicineClass of 2001
Certifications & Licensure
- DC State Medical License 2010 - 2026
- MD State Medical License 2005 - 2026
- VA State Medical License 2022 - 2026
- NY State Medical License 2003 - 2005
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy Start of enrollment: 2001 Nov 01
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Start of enrollment: 2012 Jan 01
- SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsOpen-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.Paul A Meyers, Noah Federman, Najat Daw, Peter M Anderson, Lara E Davis
Journal of Clinical Oncology. 2024-11-01 - Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.R Taylor Sundby, Jeffrey J Szymanski, Alexander C Pan, Paul A Jones, Sana Z Mahmood
Clinical Cancer Research. 2024-10-01 - Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.Marie V Nelson, AeRang Kim, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton
The Oncologist. 2024-08-05
Press Mentions
- Children’s National Hospital Becomes First Pediatric Hospital Designated a Center of Excellence by Focused Ultrasound FoundationSeptember 24th, 2020
- A Melanoma Drug Shows Promise for NF1 PlexiformsSeptember 30th, 2019
- MedCityNews – Pediatric Device Innovators Forum Explores State of Focused UltrasoundJuly 15th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: